Lyra Therapeutics (NASDAQ:LYRA) Lowered to Neutral at HC Wainwright
HC Wainwright lowered shares of Lyra Therapeutics (NASDAQ:LYRA – Free Report) from a buy rating to a neutral rating in a research note issued to investors on Tuesday, MarketBeat Ratings reports. The firm currently has $2.00 target price on the stock, down from their previous target price of $12.00. A number of other research analysts […]
More Stories
New Listings Tick Up 3 Percent as Mortgage Rates Continue to Slide
By Rob Sabo New home listings are on the rise across the United States, potentially spurred by hopes of falling...
US, EU Sign Preliminary Partnership Deal on Critical Minerals
By Owen Evans The United States and the European Union signed a memorandum of understanding on April 24 for a...
DOJ Approves Firing Squads for Federal Death Penalty Cases
By Michael Clements The Department of Justice (DOJ) has authorized firing squads, electrocution, and gassing as a means of execution...
Trump Extends Jones Act Waiver for 90 Days to Ease Energy Crunch
By Tom Ozimek President Donald Trump has extended a waiver of the century-old Jones Act for 90 days, allowing foreign-flagged...
Canada Rescinds Digital Services Tax After Trump Halts Trade Talks
By Omid Ghoreishi The Canadian government is rescinding its digital services tax to avoid stalling trade talks with the United...
Trump Floats Taxpayer-Funded Takeover of Spirit Airlines, Selling for Profit
By Chris Summers President Donald Trump said on April 23 that a taxpayer-funded takeover of Spirit Airlines could be an...